Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates

Streptococcus pneumoniae serotype 3, isolated from a penicillin-allergic patient and initially susceptible to fluoroquinolones, macrolides, lincosamides, quinupristin-dalfopristin, and telithromycin, became resistant to all these drugs during treatment. Mutations in the parC and gyrA and in the 23S...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases 2003-09, Vol.9 (9), p.1159-1162
Main Authors: Pérez-Trallero, Emilio, Marimon, José M, Iglesias, Luis, Larruskain, Julián
Format: Article
Language:English
Subjects:
Aged
Anti-Bacterial Agents - therapeutic use
Anti-Infective Agents - therapeutic use
Case studies
ciprofloxacin
clarithromycin
Dispatch
Dosage and administration
drug resistance
Drug resistance in microorganisms
Drug Resistance, Multiple, Bacterial
Drug therapy
Fluoroquinolones
Humans
Macrolide antibiotics
Macrolides
Male
Microbial Sensitivity Tests
Pneumococcal Infections - drug therapy
Point Mutation
Quinolone antibacterial agents
Quinolones
serotype 3
Streptococcus pneumoniae
Streptococcus pneumoniae - drug effects
Streptococcus pneumoniae - genetics
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Streptococcus pneumoniae serotype 3, isolated from a penicillin-allergic patient and initially susceptible to fluoroquinolones, macrolides, lincosamides, quinupristin-dalfopristin, and telithromycin, became resistant to all these drugs during treatment. Mutations in the parC and gyrA and in the 23S rRNA and the ribosomal protein L22 genes were detected in the resistant isolates.
ISSN:1080-6040
1080-6059
DOI:10.3201/eid0909.020810